Professor Mark Stevenson is an internationally renowned epidemiologist whose research and advocacy have led to transport and public health policies that have reduced the global burden of injury. His landmark research associated with mobile phone use and the risk of car crash led to legislative change across five countries. Additionally, his research on young driver crashes has influenced licensing policies in Australia and his research on toddler drownings has led to legislation requiring four-sided isolation pool fencing.

Professor Stevenson’s leadership and mentorship have been recognised, internationally, and his ability to deliver injury prevention interventions into mainstream systems, highlight the enormous utility of his work.

Professor Ben Solomon is a clinician-scientist whose clinical and translational research has identified new treatments, changed standards of care and improved outcomes for patients with lung cancer, the leading cause of cancer-related death. His work has resulted in regulatory approvals for first, second and third generation ALK TKIs, defining new and transformative standards of care in this population.

Professor Solomon’s ongoing leadership role in global clinical trials and as scientific chair and founding board member of the Thoracic Oncology Group of Australasia will ensure conduct and implementation of research that improves outcomes for lung cancer patients in Australia and worldwide.

Professor Shantha Rajaratnam’s research has taken circadian neuroscience into new clinical approaches: melatonin agonist (to FDA approval), light therapy and digital applications. He has published more than 165 peer-reviewed papers and two edited books, and he has led the peak body for sleep health and medicine (Australasian Sleep Association). He currently leads the Sleep Health Foundation.

Professor Rajaratnam was a Program Leader for the Alertness CRC (>$90 million), and a Chief Investigator on two NHMRC Centres for Research Excellence. At Monash, he established a multi-disciplinary sleep research program (now with nine labs), and a sleep research network across the university and six affiliated hospitals.

Professor Eric Morand is an internationally renowned academic physician-scientist. His career has focused on integrating clinical and laboratory science to advance patient outcomes in lupus.

Professor Morand founded a multinational consortium to design and validate new clinical endpoints, solving a decade-long impasse responsible for multiple failed trials. He led the breakthrough Phase 3 trial of the novel medicine anifrolumab, resulting in approval of only the second new medicine for lupus in 60 years and formally validating a key aspect of SLE pathogenesis. Professor Morand’s work identifying molecular targets for an alternative to steroids won the highest award of the Lupus Research Alliance, US.

Professor Laura Mackay is a Howard Hughes and Bill and Melinda Gates-funded International Scholar, Sylvia and Charles Viertel Senior Research Fellow, NHMRC Leadership Fellow and Dame Kate Campbell Fellow. She has is an internationally recognised expert in T cell immunity, contributing landmark papers that have defined how memory T cell responses are generated in body tissues (Science, Nature, Nature Immunol, Nature Medicine, Immunity).

Professor Mackay’s work has been recognized by prestigious fellowships, international grant funding, speaking invitations and Awards including The Gottschalk Medal (AAS) and Prime Minister’s Prize for Frank Fenner Life Scientist of the Year.